 CARLSBAD, Calif.--BUSINESS WIRE--- LCTX LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. NYSE American and TASE: LCTX, a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, reported today that updated interim results from a Phase 12a clinical study of its lead product candidate, OpRegen, an investigational retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration AMD, were featured in a po 